NCT00554723

CHInese Medicine NeuroAid Efficacy on Stroke Recovery

A Double Blind, Placebo Controlled, Randomized, Multicenter Study to Investigate CHInese Medicine NeuroAid Efficacy on Stroke Recovery

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,100 (actual)
• Sponsor: CHIMES Society · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

CHIMES is a double blind, placebo controlled, randomized, multicenter study to test the hypothesis that NeuroAid is superior to placebo in reducing neurological deficit and improving functional outcome in patients with cerebral infarction of an intermediate range of severity.

Detailed description

Stroke is a major cause of death and disability. Previous clinical studies performed in China have shown that NeuroAiD increase stroke patients'recovery in terms of neurological disability and functional outcome{Chen et al,2009}and thus may be beneficial as part of a post-stroke rehabilitation programme. In the CHIMES study,we seek to test the hypothesis that NeuroAiD is superior to a placebo in reducing neurological deficit and improving functional outcome in patients recruited within 72 h after the ischemic stroke with intermediate range of severity {6\<\_NIHSS\<\_14}.More details of the study protocol have recently been published {Venketasubramanian et al,2009}.

Conditions

• Cerebral Infarction
• Stroke

Interventions

Type	Name	Description
DRUG	NeuroAid	4 capsules 3 times daily, for three months
DRUG	NeuroAid matched Placebo	NeuroAid matched Placebo, 4 capsules 3 times daily, for three months

Timeline

• Start date: 2007-05-01
• Primary completion: 2012-08-01
• Completion: 2012-08-01
• First posted: 2007-11-07
• Last updated: 2014-05-01

Locations

24 sites across 6 countries: Hong Kong, Malaysia, Philippines, Singapore, Sri Lanka, Thailand